News | July 26, 2022
Sanofi India Q2 CY2022 PAT drops 49.5% to Rs. 120.4 Cr
Sanofi India has reported total income of Rs. 715 crores during the period ended June 30, 2022.
Sanofi India has reported total income of Rs. 715 crores during the period ended June 30, 2022.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Company is investing more than €100 million in the expansion of the Halle site
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
First and only PARP inhibitor to improve invasive disease-free survival in patients
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
Subscribe To Our Newsletter & Stay Updated
